CD274 and neoplasm: There is poor interobserver agreement among pathologists in scoring PD-L1 in the tumor-associated immune infiltrate, and although patients with higher PD-L1 tumor proportion score might show clear benefit with immune checkpoint inhibitor treatment, subsets of patients with negative or lower levels of PD-L1 may also respond [32].